Published Online:2 Nov 2016https://doi.org/10.4155/ppa-2016-0017
Abstract
Brazil's Pharma market is a dynamic and promising one. It ranks within the top ten market. There are peculiar hurdles that patentees have to overcome, such as, a two-tier examination, a serious backlog at the Brazilian Patent and Trademark Office. Several measures to accelerate examination have been adopted given the meager number of Examiners.
Keywords:
References
- 1 IHS Markit. www.ihs.com/.
- 2 2015 Global life sciences outlook: adapting in an era of transformation. www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-life-sciences-report.pdf.
- 3 USTR Releases Annual Special 301 Report on Intellectual Property Rights (2014). https://ustr.gov/about-us/policy-offices/press-office/press-releases/2014/April/USTR-Releases-Annual-Special-301-Report-on-Intellectual-Property-Rights.
- 4 ANVISA. http://portal.anvisa.gov.br/.
- 5 Standing Committee on Pharma and Biotechnology (2015). http://aippi.org/wp-content/uploads/2015/12/3_Pharma-and-Biotechnology.pdf.
- 6 Modernizing the Brazilian PTO. www.patentlawyermagazine.com/modernizing-the-brazilian-pto/.
- 7 Brazilian Biodiversity – Opportunities for innovation (2015). http://biominas.org.br/en/blog/2015/07/10/brazilian-biodiversity-opportunities-for-innovation/.
- 8 New ANVISA Clinical Research Regulations. www.abracro.org.br/noticias/370-new-anvisa-clinical-research-regulations.
